ICONOVIR BIO
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
ICONOVIR BIO
Industry:
Biotechnology
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.iconovir.com
Total Employee:
11+
Status:
Active
Total Funding:
77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Sitelinks Search Box
Similar Organizations
Atavistik Bio
Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Current Advisors List
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Board_member
2021-01-01
Current Employees Featured
Clodagh O’Shea Scientific Founder and SAB Chair @ IconOVir Bio
Scientific Founder and SAB Chair
John Huynh Chief Technology Officer @ IconOVir Bio
Chief Technology Officer
2022-06-01
Mark McCamish President & CEO @ IconOVir Bio
President & CEO
Founder
Investors List
Vida Ventures
Vida Ventures investment in Series A - IconOVir Bio
Polaris Partners
Polaris Partners investment in Series A - IconOVir Bio
Logos Capital
Logos Capital investment in Series A - IconOVir Bio
Nextech Invest
Nextech Invest investment in Series A - IconOVir Bio
Bellco Capital
Bellco Capital investment in Series A - IconOVir Bio
Wellington Partners
Wellington Partners investment in Series A - IconOVir Bio
GV
GV investment in Series A - IconOVir Bio
Two River
Two River investment in Series A - IconOVir Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-06 | IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer |
Official Site Inspections
http://www.iconovir.com Semrush global rank: 4.34 M Semrush visits lastest month: 2.62 K
- Host name: cloudproxy10082.sucuri.net
- IP address: 192.124.249.82
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IconOVir Bio"
About Us - IconOVir
About Us “To conquer cancer requires targeted therapies that are as genetically sophisticated and deadly as the cancer itself. In my opinion, there are no agents that have more potential than …See details»
IconOVir Bio - Crunchbase Company Profile & Funding
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer. Its oncolytic virus …See details»
IconOVir Bio - LinkedIn
IconOVir Bio | 2,282 followers on LinkedIn. Pushing the envelope: Our mission is to cure cancer and restore life to every patient everywhere | IconOVir Bio is a preclinical-stage biotechnology ...See details»
IconOVir Bio, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for IconOVir Bio, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
IconOVir Bio Announces Formation of Scientific Advisory Board
Apr 20, 2021 It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients. For more information, please …See details»
IconOVir Bio 2025 Company Profile: Valuation, Funding
IconOVir Bio was founded in 2018. Where is IconOVir Bio headquartered? IconOVir Bio is headquartered in New York, NY. What is the size of IconOVir Bio? IconOVir Bio has 14 total …See details»
IconOVir Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Feb 25, 2025 IconOVir’s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. ... The statistics for drugs in …See details»
IconOVir's Leadership Team - Team members and org chart - The …
The leadership team at IconOVir has experience in a variety of industries, including biotech, pharmaceuticals, and law. They have also been educated at some of the top schools in the …See details»
IconOVir Bio - Contacts, Employees, Board Members ... - Crunchbase
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer. ... Experience the new Crunchbase, powered by AI . …See details»
IconOVir - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 28, 2025 IconOVir is a series B company based in San Diego (United States), founded in 2020. It operates as a Developer of cancer therapeutics using the oncolytic virus. IconOVir has …See details»
IconOVir Bio - Craft
IconOVir Bio is a preclinical-stage biotechnology company that develops therapies to improve the treatment of patients with cancer. Its proprietary oncolytic virus platform is based designed to …See details»
IconOVir Bio - workinbiotech.com
Iconovir Bio is a preclinical-stage biotechnology company developing next-generation oncolytic virus therapies to improve the treatment of cancer. Oncolytic viruses are viruses that are …See details»
IconOVir uncloaks with $77M, ex-Forty Seven CEO and cancer …
Jan 5, 2021 IconOVir wants to get IOV-1042 into the clinic in the first half of 2022, McCamish said. A big focus will be on manufacturing the virus for clinical trials and designing a phase 1 …See details»
IconOVir Bio Raises $77 Million in Series A Financing to Develop …
SAN DIEGO, January 5, 2021 – IconOVir Bio, Inc., a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients …See details»
IconOVir Bio Company Profile: Overview and Full News Analysis
IconOVir Bio operates in the commercial markets of biotechnology and pharmaceuticals, focusing on the research and development of novel cancer therapies. One of the key products offered …See details»
IconOVir Bio Raises $77 Million in Series A Financing to Develop …
Jan 5, 2021 IconOVir has developed a proprietary platform to create next-generation oncolytic viruses based on more than a decade of oncolytic virus research by IconOVir’s Scientific …See details»
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical …
IconOVir’s Phase 1 clinical trial is an open-label study designed to evaluate the safety, pharmacokinetics, pharmacodynamics and biological and clinical activity of ICVB-1042 in …See details»
investors.urogen.com
Investors.urogen.comSee details»
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical …
Jul 11, 2023 IconOVir’s Phase 1 clinical trial is an open-label study designed to evaluate the safety, pharmacokinetics, pharmacodynamics and biological and clinical activity of ICVB-1042 …See details»
IconOVir Bio Announces Preclinical Proof-of-Concept Data for ...
SAN DIEGO, CA., May 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the …See details»